Detalhe da pesquisa
1.
Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
Pediatr Blood Cancer
; 69(4): e29557, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35107876
2.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617659
3.
Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients.
Support Care Cancer
; 28(9): 4193-4199, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900609
4.
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation.
J Clin Med
; 11(19)2022 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36233461
5.
MicroRNA profiling of paediatric AML with FLT-ITD or MLL-rearrangements: Expression signatures and in vitro modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors.
Oncol Rep
; 48(6)2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36321792
6.
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort.
Clin Lymphoma Myeloma Leuk
; 21(4): e328-e333, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33342728
7.
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance.
Leuk Lymphoma
; 61(14): 3476-3483, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32870062
8.
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Oncol Res Treat
; 42(12): 660-664, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31593970
9.
MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
Front Immunol
; 9: 926, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29765374
10.
Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells.
Cancers (Basel)
; 10(12)2018 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30501078